Bladder Cancer Treatment Market

Bladder Cancer Treatment Market

Global bladder cancer treatment market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Bladder cancer is a common type of cancer that begins in the cells of the bladder. The bladder is a hollow muscular organ in the lower abdomen that stores urine. Bladder cancer most often begins in the cells (urothelial cells) that line the inside of the bladder. The most common type of bladder cancer is urothelial bladder cancer. This is also called transitional cell bladder cancer. There are some rarer types. These include squamous cell bladder cancer, adenocarcinoma, sarcoma and small cell bladder cancer among others. Urothelial cancer can happen in the kidneys and ureters, too, but it's much more common in the bladder.

Bladder cancers are further classified based on how the cancer cells appear when viewed through a microscope. This is known as the grade and may describe bladder cancer as either low-grade or high-grade. Different types of treatment are available for bladder cancer. Surgical options are available for all stages of the condition, chemotherapy uses drugs to target and kill cancer cells or to shrink tumors and allow a surgeon to use a less invasive procedure, immunotherapy for early-stage bladder cancer might involve encouraging the immune system to fight cancer cells, radiation therapy is a less common intervention for bladder cancer and targeted therapy focuses on the genetic changes that turn healthy cells into cancer cells.

Market Dynamics: Drivers

Rising demand for novel therapeutics

The rising demand for novel therapeutics is expected to drive the market over the forecast period. The global incidence of bladder cancer has been on the rise, necessitating the development of more effective and targeted treatment options. As the prevalence of the disease grows, there is a corresponding need for novel therapeutics to address the diverse characteristics of bladder cancer. According to the World Health Organization (WHO), bladder cancer is the 10th most common cancer type worldwide. Every year, about 6,00,000 people are diagnosed with bladder cancer worldwide and more than 2,00,000 people die from this disease.

For instance, on January 19, 2024, Johnson & Johnson cleared the U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) for BALVERSA (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. BALVERSA is the first oral FGFR kinase inhibitor to be approved and the first and only targeted treatment for patients with mUC and FGFR alterations.

In addition, on April 13, 2021, Gilead Sciences, Inc. released that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

There is an increasing demand for novel combination therapies, which results in better patient outcomes. For instance, on December 15, 2023, Astellas Pharma Inc. and Pfizer Inc. cleared the U.S. Food and Drug Administration (FDA) approval of PADCEV (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.

Further, the increasing prevalence of bladder cancer, rising FDA approvals for novel therapies, increasing clinical trials to develop more advanced therapies, increasing awareness about the condition and treatments available and increasing advancements in developing novel therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as side effects associated with the various therapies such as chemotherapy that is put inside the bladder, such as mitomycin or gemcitabine, often cause temporary irritation of the bladder including the need to urinate frequently and urgently and pain with urination, the high cost of the treatment, complications associated with the surgery and unmet needs are the factors expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global bladder cancer treatment market is segmented based on cancer type, grade, treatment type, end-user and region.

The immunotherapy segment accounted for approximately 37.7% of the bladder cancer treatment market share

The immunotherapy segment is expected to hold the largest market share over the forecast period. Immunotherapy is the use of medicines to help a person’s immune system recognize and destroy cancer cells. These treatments are put directly into the bladder. They are used mainly for early-stage bladder cancers that haven’t grown deeply into the wall of the bladder. Bacillus Calmette-Guerin (BCG) is a type of bacteria that can be put right into the bladder as a liquid. This activates immune system cells in the bladder, which then attack the bladder cancer cells.

For instance, on October 23, 2023, ImmunityBio, Inc., a clinical-stage immunotherapy company, cleared that it has completed the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803 (Anktiva), a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.

Nadofaragene firadenovec (Adstiladrin) is made up of a virus that contains the gene to make interferon alfa-2b, an important immune system protein. When the virus is put into the bladder as part of a liquid, it delivers the gene into the cells lining the bladder wall. The cells then start making extra interferon alfa-2b, which helps the body’s immune system attack the cancer cells.

For instance, on December 16, 2022, Ferring Pharmaceuticals cleared the U.S. Food and Drug Administration (FDA) approval of Adstiladrin (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy, for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Geographical Analysis

North America accounted for approximately 41.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing prevalence of bladder cancer in the region. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies and medical device companies, which mainly focus on the development of novel therapeutics for better treatment. This presence of major players in the region collaborating and merging with other companies to develop more advanced therapies for bladder cancer.

For instance, on June 30, 2020, EMD Serono and Pfizer Inc. cleared that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

In addition, on August 31, 2021, Merck released a label update for KEYTRUDA, Merck’s anti-PD-1 therapy, for its indication in first-line advanced urothelial carcinoma (bladder cancer) in the U.S. The U.S. Food and Drug Administration (FDA) has converted this indication from an accelerated to a full (regular) approval. In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-containing chemotherapy.

Moreover, there is an increasing prevalence of bladder cancer in the region. For instance, according to the American Cancer Society’s estimates for bladder cancer in the United States for 2024 are about 83,190 new cases of bladder cancer (about 63,070 in men and 20,120 in women) and about 16,840 deaths from bladder cancer (about 12,290 in men and 4,550 in women). Thus, due to rising prevalence, there is an increasing demand for various bladder cancer therapeutics in the region.

Competitive Landscape

The major global players in the bladder cancer treatment market include Johnson & Johnson Services, Inc., Astellas Pharma Inc., Ferring Pharmaceuticals Inc., Merck & Co., Inc., Genentech, Inc., Bristol-Myers Squibb Company, Pfizer Inc., Theralase Technologies Inc., Gilead Sciences, Inc. and ImmunityBio, Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bladder cancer treatment market. The COVID-19 pandemic has resulted in delays in the treatment of patients with urological malignancies. The management of bladder cancer in particular poses a significant challenge given the recurrent nature of the disease and the intense follow-up regime required for many cases. The pandemic also temporarily disrupted the clinical trials and research activities. In addition, the supply chain of these cancer therapeutics is also disrupted globally.

Market Segmentation

By Cancer Type
• Non-Muscle Invasive Bladder Cancer
• Muscle Invasive Bladder Cancer
• Metastatic Bladder Cancer
• Urothelial (Transitional Cell) Bladder Cancer
• Squamous Cell Bladder Cancer
• Papillary Bladder Cancer
• Others

By Grade
• Low-Grade Bladder Cancer
• High-Grade Bladder Cancer

By Treatment Type
• Chemotherapy
Intravesical Chemotherapy

 Mitomycin-C

 Gemcitabine (Gemzar)

 Docetaxel (Taxotere)

 Valrubicin (Valstar)
Systemic Chemotherapy

 Cisplatin and Gemcitabine

 Carboplatin and Gemcitabine

 Mvac (Methotrexate (Rheumatrex, Trexall), Vinblastine (Velban), Doxorubicin and Cisplatin)

 Docetaxel or Paclitaxel

 Pemetrexed (Alimta)

 Others
• Radiation Therapy
• Immunotherapy
Local Immunotherapy

 Bacillus Calmette-Guerin (BCG)

 Interferon (Roferon-A, Intron A, Alferon)
Systemic Immunotherapy

 Avelumab (Bavencio)

 Nivolumab (Opdivo)

 Pembrolizumab (Keytruda)
• Targeted Therapy
Erdafitinib (Balversa)
Enfortumab Vedotin-Ejfv (Padcev)
Sacituzumab Govitecan (Trodelvy)
Others
• Surgery
Transurethral Bladder Tumor Resection (TURBT)
Radical Cystectomy and Lymph Node Dissection
Others
• Medications
• Gene Therapy
• Others

By End-User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global spinal bladder cancer market segmentation based on cancer type, grade, treatment type, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of bladder cancer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bladder cancer treatment market report would provide approximately 69 tables, 77 figures, and 198 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies